Shots:

• The P-III ASPEN-1 trial evaluating the efficacy and safety of DaxibotulinumtoxinA (either 125 unit or 250 unit dose) for injection vs PBO in adults with cervical dystonia- patients followed for a maximum of 36 wks in post-treatment
• The results showed median duration effect of up to 24 wks- as determined by time to loss of 80% peak treatment benefit- and has the potential to reduce frequency up to 50% annually- generally safe and well-tolerated
• The trial underscores the potential of therapeutics pipeline for the treatment of muscle movement and pain disorders

  Ref: BusinessWire | Image: Revance